Sign In
Buy SPRC
$6.97
-0.440 (-5.94%)
At Close: Jun 22, 2026
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
08:55am, Wednesday, 27'th Mar 2024
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
08:58am, Thursday, 21'st Mar 2024
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Compan
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
07:29am, Monday, 18'th Mar 2024
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of th
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
08:49am, Thursday, 14'th Mar 2024
First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum Disorder in pediatric patients
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
08:14am, Tuesday, 12'th Mar 2024
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Compan
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
07:11am, Friday, 08'th Mar 2024
TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
07:49am, Thursday, 07'th Mar 2024
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
04:41pm, Wednesday, 06'th Mar 2024
TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
08:35am, Thursday, 29'th Feb 2024
The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in accordance with enrollment initiat ion
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
07:58am, Tuesday, 27'th Feb 2024
TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market
Why Is SciSparc (SPRC) Stock Up 50% Today?
01:49pm, Wednesday, 24'th Jan 2024
Cannabinoid biotech specialist SciSparc (NASDAQ: SPRC ) is enjoying a much-needed boost on Wednesday thanks to a key investment deal. This morning, management announced an equity purchase agreement wi
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
07:42am, Wednesday, 24'th Jan 2024
TEL AVIV, Israel, Jan. 24, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of the
TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
